NCT03679754View on ClinicalTrials.gov

Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 5, 2018

Primary Completion Date

April 2, 2019

Study Completion Date

January 19, 2021

Conditions
Glioblastoma
Interventions
BIOLOGICAL

Ad-RTS-hIL-12

"* 2.0 x 10\^11 viral particles (vp) per injection~* intratumoral injection of Ad-RTS-hIL-12"

DRUG

veledimex

"* 20mg/day~* 15 oral daily doses of veledimex"

Trial Locations (4)

10016

NYU - Langone Health, New York

60611

Northwestern Memorial Hospital, Chicago

77030

The University of Texas MD Anderson Cancer Center, Houston

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors
All Listed Sponsors
lead

Alaunos Therapeutics

INDUSTRY